10 results on '"Wallner, K."'
Search Results
2. Urinary Incontinence in Patients Who Have a TURP/TUIP Following Prostate Brachytherapy
- Author
-
Hu, K., primary and Wallner, K., additional
- Published
- 1999
- Full Text
- View/download PDF
3. Clinical Course of Rectal Bleeding Following I-125 Prostate Brachytherapy
- Author
-
Hu, K., primary and Wallner, K., additional
- Published
- 1999
- Full Text
- View/download PDF
4. Optimized prostate brachytherapy minimizes the prognostic impact of percent of biopsy cores involved with adenocarcinoma.
- Author
-
Nurani R, Wallner K, Merrick G, Virgin J, Orio P, and True LD
- Subjects
- Adenocarcinoma blood, Adenocarcinoma pathology, Adult, Aged, Aged, 80 and over, Brachytherapy methods, Disease-Free Survival, Dose-Response Relationship, Radiation, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Staging, Prognosis, Prospective Studies, Prostate-Specific Antigen blood, Prostatic Neoplasms blood, Prostatic Neoplasms pathology, Radiotherapy Dosage standards, Risk Factors, Adenocarcinoma radiotherapy, Brachytherapy standards, Prostatic Neoplasms radiotherapy
- Abstract
Purpose: A higher percent of positive biopsy cores predicts poor biochemical failure-free survival. The highest dose covering at least 90% of the prostate is a standard method of measuring implant quality. We tested the hypothesis that the percentage of positive biopsy cores loses its adverse prognostic impact in patients who receive implants with a highest dose covering at least 90% of the prostate of 100% or greater of the prescription dose., Materials and Methods: A total of 568 patients with intermediate to high risk adenocarcinoma of the prostate who were previously treated with brachytherapy in a prospective, randomized study were evaluated. The relationship between the percentage of positive biopsy cores, the highest dose covering at least 90% of the prostate and biochemical failure was examined., Results: At a median followup of 50 months the rate of 5-year biochemical failure-free survival was 87% for the entire group and 92% vs 81% for patients with less than 50% vs 50% or greater positive biopsy cores (log rank p = 0.009). The mean highest dose covering at least 90% of the prostate was statistically lower in failing vs nonfailing cases (p = 0.03). Gleason score, prostate specific antigen, 50% or greater positive biopsy cores and the highest dose covering at least 90% of the prostate were the only statistically significant predictive factors for biochemical failure-free survival on multivariate Cox regression analysis. When regression analysis was restricted to the 237 patients who received implants with a highest dose covering at least 90% of the prostate of 100% or greater, 50% or greater positive biopsy cores lost predictive value but prostate specific antigen and Gleason score remained independent prognostic factors., Conclusions: A total of 50% or greater positive biopsy cores is an independent predictor of poor biochemical failure-free survival in patients treated with brachytherapy. High quality prostate brachytherapy, defined by a highest dose covering at least 90% of the prostate of 100% or greater, minimize the adverse effect of 50% or greater positive biopsy cores on time to biochemical failure.
- Published
- 2007
- Full Text
- View/download PDF
5. Patient reported complications after prostate brachytherapy.
- Author
-
Han BH, Demel KC, Wallner K, Ellis W, Young L, and Russell K
- Subjects
- Adult, Aged, Aged, 80 and over, Humans, Incidence, Male, Middle Aged, Patients, Surveys and Questionnaires, Brachytherapy adverse effects, Prostatic Neoplasms radiotherapy, Radiation Injuries epidemiology
- Abstract
Purpose: Prostate brachytherapy has gained popularity due partly to the low rates of short-term complications shown in studies from highly select clinical practices. These series rely on medical records generated by the treating physician and are prone to underreport complications. We summarize the complication reports obtained directly from patients to establish a more realistic incidence of treatment related problems., Materials and Methods: In 1997, 160 consecutive patients treated with prostate brachytherapy at the University of Washington were studied. A questionnaire was designed to determine the rate of complications occurring within 1 year of the procedure. The questions were formulated for ease of use and conciseness, while accounting for easily recalled events associated with complications. A total of 147 (92%) patients completed the questionnaire., Results: There were 8 (5%) patients who required hospital admission for an average of 2 days (range 1 to 7) as a result of the procedure. A total of 56 (38%) patients required nonroutine visits with a physician in an office setting or at an emergency room. Radiation proctitis diagnosed by endoscopy developed in 8 (5%) patients but no one needed surgical intervention. A total of 47 (32%) patients required urinary catheterization at some point after implantation., Conclusions: We demonstrated a higher rate of short-term complications than those previously reported. Fortunately, the majority of side effects were self-limited and no treatment related mortality or cardiovascular morbidity was seen. Our findings may provide a more realistic account of the complications likely to occur after implantation than might be surmised from previous reports.
- Published
- 2001
6. Prostate specific antigen based disease control following ultrasound guided 125iodine implantation for stage T1/T2 prostatic carcinoma.
- Author
-
Blasko JC, Wallner K, Grimm PD, and Ragde H
- Subjects
- Aged, Aged, 80 and over, Follow-Up Studies, Humans, Male, Middle Aged, Prostatic Neoplasms diagnosis, Prostatic Neoplasms mortality, Radiotherapy Dosage, Treatment Outcome, Brachytherapy, Iodine Radioisotopes administration & dosage, Monitoring, Physiologic methods, Prostate-Specific Antigen blood, Prostatic Neoplasms radiotherapy
- Abstract
Purpose: We report the prostate specific antigen (PSA) based recurrence-free survival rate after 125iodine (125I) implantation for early stage prostatic carcinoma., Materials and Methods: A total of 197 patients with clinical stage T1 and T2 prostatic carcinoma underwent outpatient 125I seed implantation. Followup was 1 to 7 years (median 3). Pretreatment serum PSA levels were elevated (greater than 4.0 ng./ml.) in 138 patients (70%). There were 105 well differentiated (Gleason score 2 to 4), 87 moderately differentiated (Gleason score 5 to 6) and 5 indeterminate tumors. The prescribed minimum prostatic dose was 160 Gy. The total dosage of 125I implanted ranged from 15 to 62 mCi. (median 37). Staging lymph node dissection and seminal vesicle biopsies were not routinely performed., Results: Among 138 patients with an elevated PSA level before implantation and no prior hormonal treatment, the PSA value returned to normal in 98% and decreased to less than 1.0 ng./ml. in 82% within 24 months of treatment. In 97% of those 138 patients the PSA level decreased to less than 1.0 ng./ml. at 48 months after implantation. Of 8 patients with an increasing PSA value 5 also had clinically evident failure. The actuarial rate of chemical (increasing PSA) or clinical failure at 5 years following implantation was 7%, with 15 patients still at risk at 5 years. There was a trend for higher failure rates among patients with higher pretreatment PSA levels (p = 0.57), Gleason scores 5 and 6 versus 2 to 4 (p = 0.51) or higher stage of disease (p = 0.17)., Conclusions: There is a high rate of clinical and chemical freedom from progression following 125I implantation for select patients with early stage prostatic carcinoma.
- Published
- 1995
7. Impact of transurethral resection on the long-term outcome of patients with prostatic carcinoma.
- Author
-
Zelefsky MJ, Whitmore WF Jr, Leibel SA, Wallner KE, and Fuks Z
- Subjects
- Actuarial Analysis, Adenocarcinoma mortality, Adenocarcinoma radiotherapy, Brachytherapy, Combined Modality Therapy, Follow-Up Studies, Humans, Iodine Radioisotopes therapeutic use, Lymph Node Excision, Male, Middle Aged, Multivariate Analysis, Prostatic Neoplasms mortality, Prostatic Neoplasms radiotherapy, Time Factors, Treatment Outcome, Adenocarcinoma surgery, Prostatectomy, Prostatic Neoplasms surgery
- Abstract
Between March 1970 and December 1987, 1,078 patients with adenocarcinoma of the prostate were treated with pelvic lymph node dissection and permanent 125iodine implantation. Before implantation, 257 patients (27%) underwent transurethral resection of the prostate, while 702 (73%) did not and their diagnosis was established by needle biopsy. A total of 119 patients (10%) underwent hormonal therapy before implantation and they were excluded from the present analysis. Clinical stage and pathological grade were similar in both groups. A higher percentage of patients in the transurethral resection group had nodal metastases at implantation. Positive lymph nodes were found in 121 patients (47%) in the transurethral resection group versus 199 (26%) who did not undergo resection (p < 0.001). The actuarial 5, 10 and 15-year distant metastasis-free survival rates among the patients who underwent transurethral resection of the prostate were 79%, 42% and 16%, respectively, compared to 86%, 52% and 27%, respectively, in the group without transurethral resection (p < 0.0001). Similarly, the actuarial disease-free and local relapse-free survival rates were significantly inferior in the transurethral resection group. A negative impact of transurethral resection of the prostate could be demonstrated among patients with grade I/II tumors. However, when stratified for nodal status, no difference in outcome in any clinical parameter was noted between the groups with and without transurethral resection of the prostate. Specifically, distant metastasis-free survival among transurethral resection group patients with negative nodes was 78%, 57% and 47% at 5, 10 and 15 years, respectively, compared to 80%, 59% and 47%, respectively, among the patients with negative nodes who did not undergo transurethral resection of the prostate (p = 0.38). Similarly, the differences between the 2 groups among patients with positive lymph nodes were not significant. When stratified by the clinical stage, grade and nodal status, the negative impact of transurethral resection of the prostate could not be demonstrated in any combination. A multivariate analysis failed to demonstrate transurethral resection of the prostate to be an independent variable in predicting the metastatic, local control or disease-free survival outcome. In conclusion, the long-term results in these pathologically staged cases indicate that transurethral resection of the prostate does not impact negatively on the clinical outcome.
- Published
- 1993
- Full Text
- View/download PDF
8. Treatment of brain metastases from bladder cancer.
- Author
-
Rosenstein M, Wallner K, Scher H, and Sternberg CN
- Subjects
- Adult, Brain Neoplasms mortality, Brain Neoplasms radiotherapy, Brain Neoplasms surgery, Carcinoma, Transitional Cell mortality, Carcinoma, Transitional Cell radiotherapy, Carcinoma, Transitional Cell surgery, Combined Modality Therapy, Female, Humans, Male, Middle Aged, Retrospective Studies, Survival Analysis, Survival Rate, Brain Neoplasms secondary, Brain Neoplasms therapy, Carcinoma, Transitional Cell therapy, Urinary Bladder Neoplasms pathology
- Abstract
The records of 28 patients with transitional cell cancer who had brain metastases were retrospectively reviewed. Data from 19 patients were considered suitable for analysis and were included in this study. One patient was treated with surgery alone, 10 with radiation alone and 7 with radiation and surgery, while 1 received no treatment. Mean and median survival times, respectively, were 57 and 42 months from the initial diagnosis, and 11 and 4 months from diagnosis of central nervous system metastases. Patients treated with surgery and radiation demonstrated a mean survival time of 19 months compared to 6 months for patients treated with radiation alone (p = 0.03). There were 2 long-term survivors in the combined modality group at 50 and at 12 months. Enthusiasm for combined modality treatment should be tempered by the fact that selection bias favored the combined modality group; 13 patients with single lesions demonstrated a mean survival of 14 months compared to 3 months for 6 patients with multiple lesions (p = 0.009) and only patients with solitary lesions underwent surgical resection. Brain metastases have an ominous prognosis in patients with bladder cancer primaries. Considering the sum of the retrospective and prospective reports, we recommend that patients with solitary brain lesions and good performance status be aggressively managed with surgical resection and postoperative radiation therapy.
- Published
- 1993
- Full Text
- View/download PDF
9. An improved method for computerized tomography-planned transperineal 125iodine prostate implants.
- Author
-
Wallner K, Chiu-Tsao ST, Roy J, Arterbery VE, Whitmore W, Jain S, Minsky B, Russo P, and Fuks Z
- Subjects
- Antigens, Neoplasm blood, Biomarkers, Tumor blood, Brachytherapy instrumentation, Carcinoma blood, Carcinoma diagnostic imaging, Humans, Male, Needles, Perineum, Prostate-Specific Antigen, Prostatic Neoplasms blood, Prostatic Neoplasms diagnostic imaging, Radiotherapy Dosage, Remission Induction, Tomography, Emission-Computed instrumentation, Brachytherapy methods, Carcinoma radiotherapy, Iodine Radioisotopes therapeutic use, Prostatic Neoplasms radiotherapy, Radiotherapy Planning, Computer-Assisted methods, Tomography, Emission-Computed methods
- Abstract
Transperineal 125iodine implants of the prostate can be performed with ultrasound guidance, a simple technique that has met with widespread acceptance. However, ultrasound does not allow good visualization of the pubic bones in relation to the pelvic outlet, and the pubic bones may interfere with needle placement in the anterior peripheral aspect of the prostate. Adequate irradiation of the entire periphery of the prostate is important to assure tumor control, since most tumors are multicentric and may involve the anterior aspect of the prostate. A computerized tomography-based treatment planning procedure that allows for angulation of transperineal needles to avoid the pubic bones and still reaches the most peripheral aspects of the gland is described. The technique also allows for the use of transrectal ultrasound and fluoroscopy to verify correct needle placement in the prostate at the procedure. Early treatment results, based on prostate specific antigen and regression of palpable tumors, are encouraging.
- Published
- 1991
- Full Text
- View/download PDF
10. 125iodine reimplantation for locally progressive prostatic carcinoma.
- Author
-
Wallner KE, Nori D, Morse MJ, Sogani PC, Whitmore WF, and Fuks Z
- Subjects
- Follow-Up Studies, Humans, Male, Radiotherapy Dosage, Time Factors, Brachytherapy, Carcinoma radiotherapy, Iodine Radioisotopes therapeutic use, Neoplasm Recurrence, Local radiotherapy, Prostatic Neoplasms radiotherapy
- Abstract
We treated 13 patients with a second 125iodine implant for local recurrence of prostatic carcinoma. All patients had biopsy proved palpable recurrence without evidence of distant metastases. Full doses of irradiation were used (median matched peripheral dose 170 Gy.). Six patients had complete regression of palpable recurrence, 2 had partial regression, 2 had no apparent response and 3 were unevaluable for local response. Actuarial freedom from local disease progression at 5 years was 51%. Despite a relatively high rate of local disease control the actuarial rate of distant metastases reached 100% at 6 years after reimplantation. There were 2 severe rectal complications and 4 instances of mild to moderate urinary incontinence among the 13 patients. Local regression of recurrent prostatic carcinoma may be achieved with 125iodine reimplantation but most patients still had distant metastases.
- Published
- 1990
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.